Company Encyclopedia
View More
name
23andMe
ME.US
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
374.78 B
ME.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
Health Care ServicesIndustry
Industry Ranking79/80
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-193.76%E
    • Profit Margin-186.98%E
    • Gross Margin66.09%A
  • Growth ScoreD
    • Revenue YoY-15.81%E
    • Net Profit YoY25.21%B
    • Total Assets YoY-54.39%E
    • Net Assets YoY-83.37%E
  • Cash ScoreD
    • Cash Flow Margin-53.48%D
    • OCF YoY-15.81%E
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreE
    • Gearing Ratio77.39%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chrome Holding Co. Delays Financial Report Filing

    Chrome Holding Co., previously 23andMe Holding Co., has announced a delay in filing its financial report due to the inability to submit Form 10-K on time. The company, along with some subsidiaries, filed for Chapter 11 bankruptcy protection on March 23, 2025, which has contributed to this delay. The upcoming earnings statement is expected to show significant changes in operational results compared to the previous fiscal year.

    Reuters·
    US
    ME
    0.00%
    Reuters·
    US
    ME
    0.00%

    Meli: Profit miss? It might just be the 'growing pains' before victory.

    The Latin American version of "Alibaba"—$Mercadolibre(MELI.US) (hereinafter referred to as Meli) released its financial report for the third quarter of 2025 on October 30. Overall, the revenue side performed well, with accelerated growth quarter-on-quarter and slightly exceeding expectations. Conversely, due to increased logistics subsidies within the e-commerce segment and a decline in financial business due to structural factors and interest rates, profit margins fell short of sell-side expectations. 1. Growth outperformed but profits underperformed: In terms of overall performance, Meli's total revenue (denominated in USD) grew approximately 39.5% year-on-year, with a significant acceleration from the previous quarter...

    US
    MELI
    +0.89%
    HK
    09988
    -1.02%
    US
    BABA
    -0.52%
    US
    MELI
    +0.89%
    HK
    09988
    -1.02%
    US
    BABA
    -0.52%

    How a DNA test solved a medical mystery – and revealed a doctor’s decades of deception

    Summer McKesson's search for answers to her medical condition led her to a DNA test that uncovered a family secret and a doctor's long-standing deception. After years of unexplained blood clots and surgeries, a geneticist diagnosed her with Marfan syndrome and a genetic clotting disorder. Curious about her family history, McKesson took a 23andMe test, discovering seven half-siblings and a connection to Dr. Charles Peete, a fertility specialist involved in a decades-old scandal affecting multiple families.

    Yahoo Finance·
    US
    MEHCQ
    0.00%
    US
    ME
    0.00%
    Yahoo Finance·
    US
    MEHCQ
    0.00%
    US
    ME
    0.00%

    23andMe Holding Submits August 2025 Operating Report

    23andMe Holding, now Chrome Holding Co., filed for Chapter 11 bankruptcy on March 23, 2025, and submitted its August 2025 operating report as part of court compliance. The report is unaudited and speculative, cautioning investors about trading risks. Spark's AI Analyst rates MEHCQ as Neutral, citing weak stock performance due to financial challenges, declining revenues, and bearish technical trends. The company's market cap is $106.9M, with a trading volume of 69,396. Improvements in financial performance are essential for restoring investor confidence.

    Tip Ranks·
    US
    ME
    0.00%
    US
    MEHCQ
    0.00%
    Tip Ranks·
    US
    ME
    0.00%
    US
    MEHCQ
    0.00%

    23andMe Files Second Amended Bankruptcy Plan

    23andMe Holding (MEHCQ) has filed a Second Amended Joint Plan in its Chapter 11 bankruptcy case, which includes new claims and a potential Equity Sale Transaction. However, court approval is uncertain, and trading remains speculative. Spark's AI Analyst rates MEHCQ as Neutral, citing weak stock performance due to declining revenues and net losses. Technical analysis indicates a bearish trend, emphasizing the need for financial improvements to boost investor confidence. Current market cap stands at $106M with an average trading volume of 73,567.

    Tip Ranks·
    US
    ME
    0.00%
    US
    MEHCQ
    0.00%
    Tip Ranks·
    US
    ME
    0.00%
    US
    MEHCQ
    0.00%
    Posts
    View More